Houston, Texas 77024

  • 19


Study of ANA001 in Moderate and Severe COVID-19 Patients

Study summary:

This is a 2 part, Phase 2/3 multi-center, double blinded, placebo-controlled study to assess the safety, tolerability, and efficacy of oral niclosamide (ANA001) in moderate and severe hospitalized COVID-19 patients compared to placebo.


Key Inclusion Criteria: 1. Provide written informed consent prior to performing study procedures 2. Hospitalized. 3. Male or female ≥18 years of age 4. Positive for severe acute respiratory syndrome coronavirus 2 5. Presence of symptoms of lower respiratory tract infection (LRTI) including at least 1 of the following: fever, cough, sore throat, malaise, headache, muscle pain, or more significant lower respiratory tract symptoms, including shortness of breath 6. At least 1 of the following: respiratory rate (RR) ≥20 breaths per minute, room air oxygen saturation (SpO2) <98%, requirement for supplemental oxygen, heart rate (HR) ≥90 beats per minute, or temperature >38.3°C 7. Women of childbearing potential must agree to abstinent or use at least 1 form of contraception not including hormonal contraception from the day of screening through Day 30 Key Exclusion Criteria: 1. Hospitalized but no longer requires ongoing inpatient care (i.e., discharge is anticipated in ≤24 hours) 2. Patient is not anticipated to survive >48 hours OR is under palliative care 2. Respiration Rate ≥30 breaths per minute, Heart Rate ≥125 beats per minute, or Oxygen Saturation (SpO2) ≤93% on ≤ 2 L/min nasal cannula oxygen 3. Evidence of critical illness, defined by at least 1 of the following: ● Respiratory failure requiring at least 1 of the following: 1. Endotracheal intubation and mechanical ventilation, oxygen delivered by high flow nasal cannula 2. Noninvasive positive pressure ventilation (NIPVV), OR 3. Extracorporeal membrane oxygenation (ECMO) or clinical diagnosis of respiratory failure - Shock (defined by systolic blood pressure (BP) <90 mm Hg, or diastolic blood pressure (BP) <60 mm Hg or requiring vasopressors), OR - Multi-organ dysfunction/failure 4. Severe central nervous system (CNS) conditions 5. Chronic kidney disease requiring dialysis 6. Known allergy to the study drug or salicylate containing medications. 7. Suspected and/or confirmed pregnancy or breastfeeding 8. Current or planned participation in any other clinical trial of a treatment being developed under a US investigational new drug (IND) or emergency use authorization (EUA). 9. Patients receiving chemotherapeutic agents and/or immunomodulators (including monoclonal antibodies (Mabs) or plasma transfusions) for chronic disease conditions. 10. Patients who receive the severe acute respiratory syndrome coronavirus 2 vaccine



Primary Contact:

Study Director
Doug Rank, MD
NeuroBo Pharmaceuticals

Akash Bakshi
Phone: 1 650-263-1270
Email: akash@neurobopharma.com

Backup Contact:

Email: andrew@neurobopharma.com
Andrew Bartynski
Phone: 1 650-263-1270

Location Contact:

Houston, Texas 77024
United States

Akash Bakshi
Phone: 650-263-1270
Email: akash@neurobopharma.com

Site Status: Recruiting

Data Source: ClinicalTrials.gov

Date Processed: September 23, 2021

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.